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LETTERS TO THE EDITOR 
Anti-inflammatory Drugs and Ischemic Heart 
Disease: New Considerations (A Cell 
Biologist's Proposal to Cardiologists) 
Dinerman and Mehta (1) presented an update of the cell to cell 
concept (2-4) in ischemic heart disease. In essence, this paracrine/ 
autocrine concept involves several inflammatory phenomena, such 
as myocardial neutrophil accumulation, leukocyte adhesion/ 
migration into the arterial intima and production of cytokines by 
activated mononuclear cells. Meanwhile, endothelial/leukocyte in-
teractions also operate in hypertension (5,6) and in ischemic brain 
lesions (7). 
The following is a brief comment on the discussion of "pharma-
cologic modification of cell-cell interactions" by Dinerman and 
Mehta (I). The authors state that pharmacologic agents, such as 
calcium antagonists and fish and fish-derived products, may benefi-
cially affect the "cardiovascular" leukocyte function. Therefore, 
this is my proposal: it is known that several diseases having an 
increased leukocyte chemotaxis feature, such as familial Mediterra-
nean fever, acute febrile neutrophilic dermatosis (Sweet's syn-
drome), necrotizing vasculitis, Beh"et's disease, are colchicine-
sensitive (8). Thus, I draw the attention of cardiologists to an 
eventual therapeutic potential of colchicine, an anti-inflammatory, 
antitubulin agent (9-13), in myocardial infarction, angina pectoris 
and coronary reocclusion after angioplasty and coronary artery 
bypass grafting. Further, after long-term oral administration (1.0 to 
1.5 mg/day), colchicine antifibrotic activity (9-13) may be an addi-
tional beneficial effect of this drug in these diseases, as shown in 
other "sclerosis" diseases, such as liver cirrhosis (14) and sclero-
derma (15). A selection of patients having colchicine-sensitive 
disease accompanied by ischemic heart disease or other atheroscle-
rotic manifestations may be studied during the respective colchicine 
therapy. This "cardiovascular" approach to colchicine-sensitive 
diseases may be an initial step of clinical trials of possible antitubulin 
(antimicrotubular) anti-inflammatory treatment in cardiovascular 
disease. 
Certainly, further experimental research will be required before 
gaining firm confidence in such an anti-inflammatory therapy of this 
disease. Colchicine is merely an example of that approach. It may 
lead to developing new and more specific drugs with anti-
inflammatory (and antifibrotic) effects in ischemic heart disease 
including angina pectoris and coronary reocclusion after angioplasty 
and coronary artery bypass grafting. 
Addendum: In two reports by cardiologists (JAMA 1963;184: 
421-2; Am Heart J 1966;71:26-8), griseofulvin therapy reduced the 
frequency of anginal attacks. Meanwhile, this drug possesses an 
anti microtubular action (16). 
I thank Dr. A.V. Costantini (Consultants Medical Group, Inc., 
San Francisco, California, USA) for valuable discussion and sup-
port. 
GEORGE N. CHALDAKOV, MD, PhD 
Laboratory of Electron Microscopy 
Varna Institute of Medicine (VIM) 
BG-9002 Varna, Bulgaria 
©1991 by the American College of Cardiology 
1445 
References 
I. Dinerman JL, Mehta JL. Endothelial, platelet and leukocyte interactions in ischemic 
heart disease: insights into potential mechanisms and their clinical relevance. J Am 
Coli Cardiol 1990:16:207-22. 
2. Forrester JS, Litvack F, Grundfest W. A perspective of coronary disease seen through 
the arteries of living man. Circulation 1987:75:505-13. 
3. Munro JM, Cortan RS. The pathogenesis of atherosclerosis: atherogenesis and 
inflammation. Lab Invest 1988:58:249-61. 
4. Hansson GK. Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atheroscle· 
rosis. Arteriosclerosis 1989:9:567-78. 
5. Hadjiisky p, Peyri N. Hypertensive arterial disease and atherogenesis. I. Intimal 
changes in the old, spontaneously hypertensive rat (SHR). Atherosclerosis 1982:44: 
181-99. 
6. Chaldakov GN. Ghenev P. Intimal and medial changes in SHR aorta (abstr). 9th 
Congress, Hungarian Arteriosclerosis Society, October 3-6,1990. 
7. Hallenbeck JM, Dutka AJ. Tanishima T, et al. Polymorphonuclear leukocyte accumu-
lation in brain regions with low blood flow during the early postischemic period. Stroke 
1986:17:246-53. 
8. Malkinson FD. Colchicine-new uses of an old, old drug. Arch Dermatol 1982;118: 
453-7. 
9. Chaldakov GN. Antitubulins-a new therapeutic approach for atherosclerosis' Ath-
erosclerosis 1982:44:385-90. 
10. Chaldakov GN, Vankov VN. Morphological aspects of secretion in the arterial smooth 
muscle cell, with special reference to the Golgi complex and microtubular cytoskele-
ton. Atherosclerosis 1986:61: 175-92. 
II. Chaldakov G, Vankov V. Antifibrotic approach in the therapy of arterial occlusive 
diseases: new considerations. In: Triibestein G, ed. Conservative Therapy of Arterial 
Occlusive Disease. Stuttgart, New York: Georg Thieme Verlag, 1986:224-6. 
12. Chaldakov GN, Deyl Z, Vankov VN. Colchicine: possible new application of its 
antifibrotic (antisecretory) action. Physiol Bohemoslov 1987;36:1-7. 
13. Hollander W, Kramsch DM, Franzblau C, et al. Suppression of atheromatous fibrous 
plaque formation by antiproliferative and antiinflammatory drugs. Circ Res (suppl 2) 
1974:34: 111-23. 
14. Kershenobich D, Uribe M, Suarez GJ, et al. Treatment of cirrhosis with colchicine. 
Gastroenterology 1979:77:532-7. 
15. Alarcon-Segovia D, Ramos-Niembro F, et al. Long-term evaluation of colchicine in the 
treatment of scleroderma. J RheumatoI1979:6:705-12. 
16. Roobol A, Gull K, Pogson ChI. Evidence that griseofulvin binds to a microtubule 
associated protein. FEBS Lett 1977:75:149-53. 
Reply 
We believe that the interactions between a variety of cellular 
elements, including endothelium smooth muscle cells, platelets and 
leukocytes, are important in various manifestations of ischemic 
heart disease, We agree with Chaldakov that inflammation is a 
common feature in early stages of atherosclerosis as well as follow-
ing mechanical injury to the coronary arteries, However, we believe 
that the spectrum of vascular injury ranges from spontaneous 
development of atherosclerosis over decades on the one hand to the 
rapid evolution of restenosis over days and months in coronary 
arteries with preexisting atherosclerosis subjected to extensive 
injury with balloons, stents and surgical trauma, on the other hand. 
Although inflammation may be one common feature of these syn-
dromes, it is unlikely that a single agent would be useful as therapy 
of all. Therefore, general observations regarding the use of any 
particular anti-inflammatory agent should be made with caution. 
The use of anti proliferative and anti-inflammatory agents was 
indeed shown to suppress atheromatous plaque formation in exper-
imental models of atherosclerosis (Chaldakov's Ref 13). However, 
use of corticosteroids which may be considered generic anti-
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inflammatory agents in prevention of restenosis after percutaneous 
transluminal coronary angioplasty did not result in favorable out-
come (I). The unfavorable outcome in trial of corticosteroids in 
prevention of restenosis is a reflection of a shotgun approach to a 
complex problem. In this context, it is important to remember that 
antiplatelet drugs, beta-adrenergic antagonists, calcium channel 
antagonists and cholesterol-lowering agents all have been shown to 
decrease or prevent atherosclerosis in experimental animals, but 
these therapies have had only modest and variable effect in man. 
Antiplatelet agents which decrease mortality in acute myocardial 
ischemia are not very effective in patients who have undergone 
coronary angioplasty. 
We noted Chaldakov's interest in colchicine and griseofulvin as 
potential therapy for mUltiple manifestation of ischemic heart dis-
ease. Indeed the role of colchicine is presently being investigated in 
prevention of restenosis of coronary arteries after angioplasty. 
However, we feel a cautious approach to use of generic anti-
inflammatory agents is warranted, because each ischemic heart 
disease syndrome may have its own peculiarities relative to its 
genesis. For example, initial thrombosis in atherosclerotic coronary 
arteries may be a platelet-dependent phenomenon, whereas re-
thrombosis after coronary thrombolysis may be due to predominant 
deposition of fibrin. 
In this era of cellular and molecular cardiology, attempts need to 
be made to define precise cellular steps in the evolution of disease 
process prior to institution of shotgun therapy. Until we understand 
the complex cellular interactions and the pathogenesis of tissue 
injury, a multi pronged therapy may need to be used. 
1.L. MEHTA, MD, PhD, FACC 
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Endothelial Cells and Not Smooth Muscle 
Cells Are Affected During a Photodynamic 
Therapy of Atherosclerotic Plaques 
Dartsch et al. (I) question why atherosclerotic plaque smooth 
muscle cells are in vitro more sensitive to hematoporphyrin-
derivative photodynamic therapy than synthetic phenotype normal 
smooth muscle cells although the former manifest a lower prolifer-
ative activity than the latter. The easiest and most probably the 
correct explanation is that these cells are not identical as it is 
assumed conventionally. It must not be forgotten that a concept of 
the medial smooth muscle cell behaving as multi potential mesen-
chyme is based on the studies carried out in vitro and, if in vivo, 
then only on nonhuman material (2). In other words, it has never 
been proved in human atherosclerosis that synthetic phenotype 
smooth muscle cells of a plaque derive from fully differentiated 
medial smooth muscle cells. 
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Recently, undifferentiated vascular endothelial cells or postem-
bryonic undifferentiated mesenchymal cells (3) were described in 
coronary allograft atherosclerosis (4). As far as I know this is the 
first evidence that the same cells may form capillary sprouts in the 
periarterial space, infiltrate the arterial wall and participate in a 
formation of intimal thickening. This observation is in keeping with 
the fact that scientists had presumed since long ago that the vasa 
va sorum were involved in a reaction of the arterial wall to injury but 
had not realized how the vasa vasorum could contribute to intimal 
thickening (5). Only recently, Diaz-Florez and Dominguez (6) and 
Sarkisov et al. (7) proposed that intimal thickening fibroblastic cells 
derive from capillary cells. Their communications inspired me to 
review the older literature concerning this subject. It came as a 
surprise to me to learn that Winternitz et al. (8) almost succeeded in 
defining a histogenesis of the atherosclerotic plaque in 1938(!). 
These authors visualized round clear cells surrounded by collag-
enous fibers into the cytoplasm of which red blood cells were 
penetrating (their Fig. 76). These cells are undifferentiated capillary 
endothelial cells which may differentiate into smooth muscle cells 
and fibroblasts or redifferentiate into flat vascular endothelial cells. 
A great many undergo necrosis leaving red blood cells behind them 
among collagenous fibers (their Fig. 89). When accentuated, this 
process may lead to arterial dissection (their Fig. 96). As far as this 
pathologic phenomenon is concerned, the observation ofWinternitz 
et al. (8) also fell into oblivion (9). These authors did not realize, 
however, the relation between the differentiated and undifferenti-
ated endothelial cells and between the undifferentiated endothelial 
and smooth muscle cells, considering the former to be an inflamma-
tory mononuclear cell phagocytizing erythrocytes (p 114). This fact 
does not diminish their merits because Winternitz et al. (8) ulti-
mately drew a correct conclusion from their observations: "The 
response to injury is mediated through the capillary bed and is 
manifested by two more or less distinct and variably proportioned 
reactions: exudation and proliferation .... Proliferation consists of 
new formation of blood vessels and connective tissue elements, 
including fibroblasts and many varieties of mononuclear cells." 
Undifferentiated capillary endothelial cells migrate during angio-
genesis (10) and therefore possess contractile myofilaments. Conse-
quently, they may be perceived as myofibroblasts or mistaken for 
synthetic phenotype smooth muscle cells. 
This information helps us to understand why atherosclerotic 
plaque cells are more sensitive to hematoporphyrin derivative 
photodynamic therapy than medial smooth muscle cells. Vascular 
endothelial cells manifest a particular affinity for photosensitizers 
such as porphyrins in both experimental (II) or clinical (12) situa-
tions. 
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